Ropanicant
 | |
| Clinical data | |
|---|---|
| Other names | SUVN-911 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H13ClN2O |
| Molar mass | 224.69 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and other neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects.[1] By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.
Clinical trials
[edit]The compound has completed Phase 1 and Phase 2 clinical trials for moderate to severe major depressive disorder.[2][1] Preliminary studies have explored its potential for a faster onset of action compared to conventional antidepressants.[3] In addition to its investigation in depression, ongoing research is examining its possible use in treating neurodegenerative disorders such as Alzheimer’s disease.[4]
See also
[edit]References
[edit]- ^ a b Nirogi R, Abraham R, Jayarajan P, Goura V, Kallepalli R, Medapati RB, et al. (July 2022). "Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization". Psychopharmacology. 239 (7): 2215–2232. doi:10.1007/s00213-022-06108-6. PMID 35298691.
- ^ Nirogi R, Benade V, Goyal VK, Pandey SK, Mohammed AR, Shinde A, et al. (September 2022). "Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects". Clinical Drug Investigation. 42 (9): 747–762. doi:10.1007/s40261-022-01189-9. PMID 35963959.
- ^ Nirogi R, Mohammed AR, Shinde AK, Ravella SR, Bogaraju N, Subramanian R, et al. (March 2020). "Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression". Journal of Medicinal Chemistry. 63 (6): 2833–2853. doi:10.1021/acs.jmedchem.9b00790. PMID 32026697.
- ^ Kocienski P (June 2020). "Synthesis of SUVN-911". Synfacts. 16 (626): 0626. doi:10.1055/s-0040-1707534.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |